论文部分内容阅读
目的研究达英-35与二甲双胍的联合使用在多囊卵巢综合症(PCOS)内分泌代谢紊乱治疗中的临床应用价值。方法选取医院在2011年2月-2014年2月收治的86例PCOS内分泌代谢紊乱患者的临床资料,随机将患者分为观察组和对照组各43例,对照组单纯采用达英-35治疗,观察组在对照组基础上采用二甲双胍治疗,比较2组患者治疗前后的三酰甘油、总胆固醇、促卵泡素、血清睾酮、黄体生成素、低密度脂蛋白胆固醇、INS指标变化情况。结果观察组总有效率为95.3%优于对照组总有效率为83.7%,差异具有统计学意义(P<0.05)。治疗后,观察组指标改善情况优于对照组,差异具有统计学意义(P<0.05)。结论通过采用达英-35与二甲双胍联合治疗后,患者相关指标有明显改善,有利于使患者内分泌代谢紊乱现象得以改善,值得临床推广应用。
Objective To study the clinical value of combined use of darun-35 and metformin in the treatment of endocrine and metabolic disorders in patients with polycystic ovary syndrome (PCOS). Methods The clinical data of 86 patients with PCOS with endocrine and metabolic disorders admitted in our hospital from February 2011 to February 2014 were randomly divided into observation group (43 cases) and control group (43 cases). The control group was treated with da-Ying-35 The observation group was treated with metformin on the basis of the control group. The changes of triglyceride, total cholesterol, follicle stimulating hormone, serum testosterone, luteinizing hormone, low density lipoprotein cholesterol and INS were compared between the two groups before and after treatment. Results The total effective rate was 95.3% in the observation group and 83.7% in the control group, the difference was statistically significant (P <0.05). After treatment, the observation group improved better than the control group, the difference was statistically significant (P <0.05). Conclusion The combination of up-Ying-35 with metformin significantly improved the relevant indicators of patients, which is conducive to the patient’s endocrine and metabolic disorders can be improved, worthy of clinical application.